Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
Yamo Pharma's Phase 2 data at INSAR 2025 show L1-79 delivers statistically significant and clinically meaningful improvements in core autism symptoms.
-
Yamo Pharmaceuticals announces positive topline results from Phase 2 study evaluating L1-79 in adolescents and young adults with autism spectrum disorder
-
Yamo Pharmaceuticals LLC has completed enrollment in its Phase 2 study evaluating L1-79 in adolescents with autism spectrum disorder (ASD).
-
New York, Jan. 27, 2022 (GLOBE NEWSWIRE) -- Yamo Pharmaceuticals, a clinical stage pharmaceutical company developing a novel therapy for the core symptoms of autism spectrum disorder (ASD), today...
-
New York, Nov. 10, 2021 (GLOBE NEWSWIRE) -- Yamo Pharmaceuticals, LLC, a clinical stage pharmaceutical company developing a novel therapy for the core symptoms of the autism spectrum disorder (ASD),...
-
New York , May 14, 2019 (GLOBE NEWSWIRE) -- Yamo Pharmaceuticals, LLC, a clinical stage pharmaceutical company developing a novel therapy for autism spectrum disorder (ASD), announced the...
-
New York, May 14, 2018 (GLOBE NEWSWIRE) -- Yamo Pharmaceuticals, LLC, a clinical stage pharmaceutical company developing a novel therapy for autism spectrum disorder (ASD), announced today that the...